For people with severe sickle cell disease (SCD) and transfusion-dependent Beta Thalassemia (TDT) treatment options are indeed limited. Utilizing the latest CRISPR-Cas-9 gene editing technology, Casgevy offers patients the highest level of personalized treatment without donor-related complications because the donor is actually the patient - setting the stage for a real cure. 

APOL1 variants are key predictors of the development of Kidney Disease (KD) and for Black patients, the risk is 70% higher than for the general population. In the next 3-4 years, 

Vertex will be seeking FDA approval for the first KD drug, specifically designed for patients of color. This HCP unbranded marketing campaign is designed to communicate

the importance of APOL1 genotyping, thereby enabling better disease progression and improved outcomes.